<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>BioScreening.net &#187; FDA News</title>
	<atom:link href="http://www.bioscreening.net/category/industry-trends/fda-news/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.bioscreening.net</link>
	<description>BioScreening news and events</description>
	<lastBuildDate>Thu, 29 Dec 2011 08:21:20 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3</generator>
		<item>
		<title>FDA Clears Abbott’s Confirmatory Chagas Disease Assay</title>
		<link>http://www.bioscreening.net/2011/11/22/first-clinical-trial-of-autologous-cardiac-stem-cells-shows-positive-results/</link>
		<comments>http://www.bioscreening.net/2011/11/22/first-clinical-trial-of-autologous-cardiac-stem-cells-shows-positive-results/#comments</comments>
		<pubDate>Tue, 22 Nov 2011 19:10:22 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cell Analysis]]></category>
		<category><![CDATA[DNA Reasearch]]></category>
		<category><![CDATA[FDA News]]></category>
		<category><![CDATA[Genetics & Pharmacogenetics]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Reports]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1340</guid>
		<description><![CDATA[FDA approved Abbott’s in vitro enzyme strip assay for Chagas disease. The Abbott ESA Chagastest detects antibodies to the causative pathogen Trypanosoma cruzi in serum or plasma samples. It is indicated for use as an additional, more specific test on human samples that have been found to be repeatedly reactive using a licensed screening test. The T. cruzi parasite is transmitted through contact with [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/11/22/first-clinical-trial-of-autologous-cardiac-stem-cells-shows-positive-results/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Genentech to Appeal to F.D.A. for Breast Cancer Drug</title>
		<link>http://www.bioscreening.net/2011/06/27/genentech-to-appeal-to-f-d-a-for-breast-cancer-drug/</link>
		<comments>http://www.bioscreening.net/2011/06/27/genentech-to-appeal-to-f-d-a-for-breast-cancer-drug/#comments</comments>
		<pubDate>Mon, 27 Jun 2011 15:10:56 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[FDA News]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1182</guid>
		<description><![CDATA[Genentech this week will step up its efforts to keep the drug Avastin available as a treatment for breast cancer, urging the Food and Drug Administration to give it one more chance to prove the medicine works. At a hearing on Tuesday and Wednesday in suburban Washington, Genentech will ask the F.D.A. to reconsider its [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/06/27/genentech-to-appeal-to-f-d-a-for-breast-cancer-drug/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pfizer&#8217;s Remoxy Fails to Win FDA Approval</title>
		<link>http://www.bioscreening.net/2011/06/24/pfizers-remoxy-fails-to-win-fda-approval/</link>
		<comments>http://www.bioscreening.net/2011/06/24/pfizers-remoxy-fails-to-win-fda-approval/#comments</comments>
		<pubDate>Fri, 24 Jun 2011 15:13:22 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[FDA News]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1175</guid>
		<description><![CDATA[WASHINGTON &#8212; The latest attempt at an abuse-resistant formulation of oxycodone (Remoxy) failed to win approval from the FDA, according to a statement from Pfizer. Late Thursday, the company said it had received a complete response letter from the FDA, which described the reasons for the FDA&#8217;s decision. The FDA had turned down an earlier [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/06/24/pfizers-remoxy-fails-to-win-fda-approval/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New Drug Effectively Treats Hepatitis C</title>
		<link>http://www.bioscreening.net/2011/06/23/new-drug-effectively-treats-hepatitis-c/</link>
		<comments>http://www.bioscreening.net/2011/06/23/new-drug-effectively-treats-hepatitis-c/#comments</comments>
		<pubDate>Thu, 23 Jun 2011 20:36:04 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[FDA News]]></category>
		<category><![CDATA[Hepatitis Research]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[R & D]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1172</guid>
		<description><![CDATA[WEDNESDAY, June 22 (HealthDay News) &#8212; The recently approved drug Incivek, combined with two standard drugs, is highly effective at treating hepatitis C, a notoriously difficult-to-manage liver disease, two new studies show. The drug works not only in patients just starting treatment, but in those who failed earlier treatment, the research found. The hepatitis C [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/06/23/new-drug-effectively-treats-hepatitis-c/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pfizer, Acura Say FDA Clears Painkiller Oxecta</title>
		<link>http://www.bioscreening.net/2011/06/21/pfizer-acura-say-fda-clears-painkiller-oxecta/</link>
		<comments>http://www.bioscreening.net/2011/06/21/pfizer-acura-say-fda-clears-painkiller-oxecta/#comments</comments>
		<pubDate>Tue, 21 Jun 2011 15:02:18 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[FDA News]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1166</guid>
		<description><![CDATA[Pfizer Inc. and Acura Pharmaceuticals Inc. said Monday the Food and Drug Administration approved a powerful painkiller that is designed to be harder to abuse. The FDA cleared marketing of Oxecta as an immediate-release treatment for moderate to severe pain. The drug is designed to discourage common methods of abuse like crushing or dissolving, and [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/06/21/pfizer-acura-say-fda-clears-painkiller-oxecta/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>UPDATE 1-Pfizer stop-smoking pill raises heart risk-FDA</title>
		<link>http://www.bioscreening.net/2011/06/17/update-1-pfizer-stop-smoking-pill-raises-heart-risk-fda/</link>
		<comments>http://www.bioscreening.net/2011/06/17/update-1-pfizer-stop-smoking-pill-raises-heart-risk-fda/#comments</comments>
		<pubDate>Fri, 17 Jun 2011 15:13:48 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[FDA News]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1163</guid>
		<description><![CDATA[WASHINGTON, June 16 (Reuters) &#8211; Pfizer Inc&#8217;s (PFE.N) stop-smoking drug Chantix can lead to a small increase in cardiovascular problems such as heart attacks for patients who already have cardiovascular disease, U.S. drug regulators said on Thursday. The Food and Drug Administration is changing the label for Chantix after reviewing the results of a clinical [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/06/17/update-1-pfizer-stop-smoking-pill-raises-heart-risk-fda/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Blood pressure drugs not linked to cancer risk, says FDA</title>
		<link>http://www.bioscreening.net/2011/06/03/blood-pressure-drugs-not-linked-to-cancer-risk-says-fda/</link>
		<comments>http://www.bioscreening.net/2011/06/03/blood-pressure-drugs-not-linked-to-cancer-risk-says-fda/#comments</comments>
		<pubDate>Fri, 03 Jun 2011 19:05:25 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[FDA News]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1132</guid>
		<description><![CDATA[A type of blood pressure-lowering medication known as angiotensin receptor blockers won’t increase a patient’s risk for cancer, the Food and Drug Administration said this week. So those taking the drugs for high blood pressure can just…relax. Concern about the drugs&#8217; possible link to cancer risk arose last year after an analysis of several studies suggested [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/06/03/blood-pressure-drugs-not-linked-to-cancer-risk-says-fda/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>WHO Says Cell Phones May Cause Cancer</title>
		<link>http://www.bioscreening.net/2011/05/31/who-says-cell-phones-may-cause-cancer/</link>
		<comments>http://www.bioscreening.net/2011/05/31/who-says-cell-phones-may-cause-cancer/#comments</comments>
		<pubDate>Tue, 31 May 2011 20:09:13 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[FDA News]]></category>
		<category><![CDATA[Oncology Research]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1122</guid>
		<description><![CDATA[A work group of the World Health Organization has declared the radiofrequency electromagnetic fields emitted by cell phones to be &#8220;possibly carcinogenic to humans.&#8221; The declaration was made after a week-long meeting of the International Agency for Research on Cancer (IARC) in Lyon, France, which involved 31 scientists from 14 countries, who decided there was [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/05/31/who-says-cell-phones-may-cause-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Okays New HIV Drug</title>
		<link>http://www.bioscreening.net/2011/05/20/fda-okays-new-hiv-drug/</link>
		<comments>http://www.bioscreening.net/2011/05/20/fda-okays-new-hiv-drug/#comments</comments>
		<pubDate>Fri, 20 May 2011 17:56:02 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[FDA News]]></category>
		<category><![CDATA[HIV Research]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1108</guid>
		<description><![CDATA[WASHINGTON &#8212; The FDA has approved rilpivirine (Edurant) for the treatment of HIV patients who have not yet begun therapy. The drug, a non-nucleoside reverse transcriptase inhibitor, is intended to be used as part of highly active anti-retroviral therapy (HAART) with at least two other medications, the agency said. Rilpivirine, also known as TMC278, is [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/05/20/fda-okays-new-hiv-drug/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Hazardous and untested flame retardants pervasive in baby products</title>
		<link>http://www.bioscreening.net/2011/05/19/hazardous-and-untested-flame-retardants-pervasive-in-baby-products/</link>
		<comments>http://www.bioscreening.net/2011/05/19/hazardous-and-untested-flame-retardants-pervasive-in-baby-products/#comments</comments>
		<pubDate>Thu, 19 May 2011 20:48:41 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[FDA News]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1103</guid>
		<description><![CDATA[A study of products designed for babies and toddlers – including car seats, nursing pillows, changing pads, bassinet mattresses and other items made with polyurethane foam – found that 80% of products tested contained chemical flame retardants considered toxic, according to a peer-reviewed study published today in the Environmental Science &#38; Technology Journal. The same flame retardants are [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/05/19/hazardous-and-untested-flame-retardants-pervasive-in-baby-products/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Soy food safe for breast cancer</title>
		<link>http://www.bioscreening.net/2011/04/06/soy-food-safe-for-breast-cancer/</link>
		<comments>http://www.bioscreening.net/2011/04/06/soy-food-safe-for-breast-cancer/#comments</comments>
		<pubDate>Wed, 06 Apr 2011 13:46:12 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[FDA News]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[Reports]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1089</guid>
		<description><![CDATA[A new study has revealed that soy food consumption does not increase the risk of cancer recurrence or death among survivors of breast cancer. Researchers investigated the association between soy food intake and breast cancer outcomes among survivors, using data from a multi-institution collaborative study, the After Breast Cancer Pooling Project. &#8220;There has been widespread [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/04/06/soy-food-safe-for-breast-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>UPDATE 1-US panel says Optimer&#8217;s antibiotic effective</title>
		<link>http://www.bioscreening.net/2011/04/05/update-1-us-panel-says-optimers-antibiotic-effective/</link>
		<comments>http://www.bioscreening.net/2011/04/05/update-1-us-panel-says-optimers-antibiotic-effective/#comments</comments>
		<pubDate>Tue, 05 Apr 2011 18:51:34 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[FDA News]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1086</guid>
		<description><![CDATA[Optimer Pharmaceuticals Inc&#8217;s (OPTR.O) experimental antibiotic is safe and effective in treating a bacterial infection that causes diarrhea, a U.S. advisory panel said on Tuesday. The advisory panel of 13 independent experts voted unanimously that the drug was effective but said there were concerns regarding the drug&#8217;s use in pregnant women and children. However, the [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/04/05/update-1-us-panel-says-optimers-antibiotic-effective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Higher bleeding risk seen in J&amp;J, Bayer clot drug</title>
		<link>http://www.bioscreening.net/2011/04/05/higher-bleeding-risk-seen-in-jj-bayer-clot-drug/</link>
		<comments>http://www.bioscreening.net/2011/04/05/higher-bleeding-risk-seen-in-jj-bayer-clot-drug/#comments</comments>
		<pubDate>Tue, 05 Apr 2011 18:44:59 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[FDA News]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[Reports]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1084</guid>
		<description><![CDATA[A blood clot preventer from Johnson &#38; Johnson and Bayer caused a surprisingly high rate of bleeding in a trial of patients with acute illnesses, representing a significant setback for the drugmakers. Bayer AG shares fell 3.6 percent in Frankfurt on Tuesday. J&#38;J slid 0.6 percent on the New York Stock Exchange. Industry analysts had [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/04/05/higher-bleeding-risk-seen-in-jj-bayer-clot-drug/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Panel calls for new safety review of mercury dental fillings</title>
		<link>http://www.bioscreening.net/2010/12/15/panel-calls-for-new-safety-review-of-mercury-dental-fillings/</link>
		<comments>http://www.bioscreening.net/2010/12/15/panel-calls-for-new-safety-review-of-mercury-dental-fillings/#comments</comments>
		<pubDate>Wed, 15 Dec 2010 14:21:11 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[FDA News]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1058</guid>
		<description><![CDATA[Updated data on mercury amalgam dental fillings may indicate possible medical problems for patients, a Food and Drug Administration advisory committee said Wednesday. The panel &#8212; after hearing two days of testimony from experts, members of the public and dental professionals &#8212; recommended the FDA look at information updated since the agency ruled in 2009 [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/12/15/panel-calls-for-new-safety-review-of-mercury-dental-fillings/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Consumers Union Raises Concerns About Mercury in Tuna</title>
		<link>http://www.bioscreening.net/2010/12/13/consumers-union-raises-concerns-about-mercury-in-tuna/</link>
		<comments>http://www.bioscreening.net/2010/12/13/consumers-union-raises-concerns-about-mercury-in-tuna/#comments</comments>
		<pubDate>Mon, 13 Dec 2010 21:15:31 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[FDA News]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1051</guid>
		<description><![CDATA[Younger women and children should limit the amount of tuna they eat and pregnant women should not eat tuna at all, because of mercury levels found in the canned and packaged fish, says new report in the January 2011 issue of Consumer Reports. Albacore or white tuna usually contains far more mercury than light tuna, [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/12/13/consumers-union-raises-concerns-about-mercury-in-tuna/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>US launches new regulatory science programm</title>
		<link>http://www.bioscreening.net/2010/05/13/us-launches-new-regulatory-science-programm/</link>
		<comments>http://www.bioscreening.net/2010/05/13/us-launches-new-regulatory-science-programm/#comments</comments>
		<pubDate>Thu, 13 May 2010 14:05:24 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[FDA News]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/05/13/us-launches-new-regulatory-science-programm/</guid>
		<description><![CDATA[Two majorÂ US government agencies have partnered to create a new regulatory science programme to ensure better integration between cutting edge science and regulatory processes in assessing new medical products or compounds flowing from biomedical research. Announced on 24 February, the effort is a joint venture of the US National Institutes of Health (NIH) and the [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/05/13/us-launches-new-regulatory-science-programm/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Slow procedure</title>
		<link>http://www.bioscreening.net/2009/12/14/slow-procedure/</link>
		<comments>http://www.bioscreening.net/2009/12/14/slow-procedure/#comments</comments>
		<pubDate>Mon, 14 Dec 2009 21:29:49 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[FDA News]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/12/14/slow-procedure/</guid>
		<description><![CDATA[Slow procedure It takes 15 years on average for a drug discovery to make it to a patient&#8217;s medicine cabinet. Throughout the process, the U.S. Food and Drug Administration requires drug companies to submit applications to proceed to the next step. 1 Drug discovery and preclinical research (three to six years) â€“ Researchers search for [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/12/14/slow-procedure/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>PharmaGap Reports That GAP-107B8 Showed Strong and Consistent Anti-Cancer Activity in a Wide Range of Cancers in NCI Test</title>
		<link>http://www.bioscreening.net/2009/12/02/pharmagap-reports-that-gap-107b8-showed-strong-and-consistent-anti-cancer-activity-in-a-wide-range-of-cancers-in-nci-test/</link>
		<comments>http://www.bioscreening.net/2009/12/02/pharmagap-reports-that-gap-107b8-showed-strong-and-consistent-anti-cancer-activity-in-a-wide-range-of-cancers-in-nci-test/#comments</comments>
		<pubDate>Wed, 02 Dec 2009 16:26:15 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[FDA News]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/12/02/pharmagap-reports-that-gap-107b8-showed-strong-and-consistent-anti-cancer-activity-in-a-wide-range-of-cancers-in-nci-test/</guid>
		<description><![CDATA[OTTAWA, ONTARIO, Oct 27, 2009 (MARKETWIRE via COMTEX) &#8212;-PharmaGap Inc. (TSX VENTURE: GAP)(OTCBB: PHRGF) (&#8220;PharmaGap&#8221; or &#8220;the Company&#8221;) is pleased to announce highly positive results from the United States National Cancer Institute (&#8220;NCI&#8221;) 5-dose in vitro anti-cancer screen of PharmaGap drug GAP-107B8. These results confirm and extend results announced in August from the single-dose study [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/12/02/pharmagap-reports-that-gap-107b8-showed-strong-and-consistent-anti-cancer-activity-in-a-wide-range-of-cancers-in-nci-test/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>CytRx Unveils Clinical Development Plan for Pipeline Assets</title>
		<link>http://www.bioscreening.net/2008/12/12/cytrx-unveils-clinical-development-plan-for-pipeline-assets/</link>
		<comments>http://www.bioscreening.net/2008/12/12/cytrx-unveils-clinical-development-plan-for-pipeline-assets/#comments</comments>
		<pubDate>Fri, 12 Dec 2008 18:47:19 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Compound Screening]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[FDA News]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Research Projects]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2008/12/12/cytrx-unveils-clinical-development-plan-for-pipeline-assets/</guid>
		<description><![CDATA[Names World-Renowned Cancer Drug Expert Dr. Joseph Rubinfeld as Chief Scientific Advisor LOS ANGELES&#8211;(BUSINESS WIRE)&#8211;CytRx Corporation (NASDAQ: CYTR) today unveiled its corporate strategy to focus its internal resources on the clinical development of oncology drug candidates tamibarotene and INNO-206, which the Company believes offer the greatest mix of near-term and medium-term revenue potential among its [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2008/12/12/cytrx-unveils-clinical-development-plan-for-pipeline-assets/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Issues Public Health Advisory on Chantix</title>
		<link>http://www.bioscreening.net/2008/04/09/fda-issues-public-health-advisory-on-chantix/</link>
		<comments>http://www.bioscreening.net/2008/04/09/fda-issues-public-health-advisory-on-chantix/#comments</comments>
		<pubDate>Wed, 09 Apr 2008 15:59:14 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotech & Pharma Law]]></category>
		<category><![CDATA[FDA News]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2008/04/09/fda-issues-public-health-advisory-on-chantix/</guid>
		<description><![CDATA[The U.S. Food and Drug Administration (FDA) today issued a Public Health Advisory to alert health care providers, patients, and caregivers to new safety warnings concerning Chantix (varenicline), a prescription medication used to help patients stop smoking. On Nov. 20, 2007, FDA issued an Early Communication to the public and health care providers that the [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2008/04/09/fda-issues-public-health-advisory-on-chantix/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

